Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 676 across all filing types
Latest filing 2025-08-28 Board/Management Inform…
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Change in Management
Board/Management Information Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the appointment of a secretarial auditor, M/s. RVR & Associates, approved by shareholders at the 47th Annual General Meeting. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and provides details about the appointment and the firm's profile. There are no financial statements, earnings data, or detailed management discussion. The document is an announcement of a board/management related change (appointment of auditors) rather than a full report or financial filing. Therefore, it fits best under Board/Management Information (MANG). The document length is moderate and contains detailed information about the appointment, not just a brief notice, supporting this classification.
2025-08-28 English
Change in Director(s)
Board/Management Information Classification · 95% confidence The document is a formal letter addressed to stock exchanges informing about the reappointment of an Independent Director, Mr. Essaji Goolam Vahanvati, following a shareholder approval at the Annual General Meeting (AGM). It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, specifically Regulation 30, which pertains to disclosures about changes in directors or key managerial personnel. The document includes details about the director's profile and the terms of reappointment. There is no financial data, earnings information, or report publication mentioned. The content is clearly about a change in the company's board of directors, which fits the category of Board/Management Information (MANG). The document length is 4250 characters, which is consistent with a detailed announcement rather than a full report. Therefore, the appropriate classification is MANG with high confidence.
2025-08-28 English
Shareholders meeting
Regulatory Filings
2025-08-28 English
Shareholders meeting
AGM Information Classification · 95% confidence The document is a detailed communication dated August 28, 2025, regarding the proceedings of the 47th Annual General Meeting (AGM) of Gland Pharma Limited. It includes speeches and presentations by the Executive Chairman and CEO, detailed financial performance for fiscal year 2024-25, strategic outlook, ESG commitments, and operational highlights. The content is comprehensive and focused on the AGM event, including the presentation materials and the meeting proceedings. There is no indication that this is a full Annual Report (10-K) or an Earnings Release (ER), but rather materials and proceedings related to the AGM. The document explicitly states it is the "Proceedings of the 47th Annual General Meeting" and includes presentations and speeches given at the AGM. Therefore, the document fits the category of AGM Information (AGM-R). The length and detail confirm it is not a mere announcement or a short notice but actual AGM materials and proceedings.
2025-08-28 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Gland Pharma has received USFDA approval for a pharmaceutical product (Vasopressin 5% Dextrose Injection). It is addressed to stock exchanges and references regulatory compliance under SEBI Listing Obligations. The content focuses on the approval news and product details, not on financial results, management changes, or detailed reports. The document length is 4196 characters, which is relatively short and typical for an announcement. There is no financial data, no detailed report, no meeting materials, or voting results. This fits the category of a Capital/Financing Update or Regulatory Filing. However, since it is about product approval and not fundraising or capital structure changes, it is best classified as a Regulatory Filing (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2025-08-26 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges notifying them about the schedule of upcoming analyst and institutional investor meetings. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulation 30, which mandates disclosure of material events including investor meetings. The content is an announcement of scheduled meetings rather than a report or detailed financial data. The document length is short (1897 characters), and it does not contain financial statements, management discussion, or detailed presentations. Therefore, it is best classified as an Investor Presentation (IP) update or announcement. However, since it is only a schedule notification without detailed presentation content, it fits best under Regulatory Filings (RNS) as a general regulatory announcement. Given the specificity of the content and the regulatory context, the classification is Regulatory Filings (RNS) with high confidence.
2025-08-25 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.